Asia
Teva got a nice shot in the arm after reports that billionaire investor Warren Buffett took a stake in the company.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The company reported positive results from early studies in 35 patients with a type of blood cancer last year.
InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research.
Beijing’s Tsinghua University will invest $276M in a JV to build a new biohub in the UK’s Cambridge Science Park.
The federal watchdog has cleared the updated design and labeling for the duodenoscope.
Haichang, at its own expense, will develop its updated RX-0201 through proof-of-concept in China.
Says the co will invest 150 million yuan to set up an investment fund with initial fund size of 250 million yuan.
Less than two months into the year, Teva’s new chief has already effectively written off a recovery for 2018.
It’s starting to feel like Teva can’t catch a break.
PRESS RELEASES